Trump Strikes Landmark Deals to Reshape U.S. Drug Pricing Landscape

Donald Trump has announced a series of high-profile deals with major pharmaceutical companies aimed at lowering prescription drug prices in the United States. The first of these agreements, with Pfizer, introduces a “most-favored nation” pricing policy, meaning that Americans will pay no more than consumers in other developed countries for certain medications. Under the deal, Pfizer will also sell select drugs directly to consumers through a new federal platform called TrumpRx.gov, expected to launch in 2026. In exchange, the company will receive a three-year reprieve from certain pharmaceutical import tariffs and will invest roughly $70 billion in U.S. manufacturing and research.  

The Trump administration is now pursuing similar arrangements with other major drugmakers including Eli Lilly, Novo Nordisk, and AstraZeneca. These negotiations are expected to make popular weight-loss drugs such as Ozempic and Mounjaro available at significantly lower prices, potentially around $149 per month. Participating companies will receive tariff relief and favorable regulatory treatment in return for commitments to produce domestically and maintain transparent pricing structures. Supporters of the initiative see it as one of Trump’s most aggressive efforts to lower drug prices by leveraging trade and regulatory power. Critics, however, argue that the impact may be limited, as many Americans obtain prescriptions through insurance or Medicaid, which already negotiate discounted rates. Questions remain about how transparent and enforceable the agreements will be, and whether the program will fundamentally change how the pharmaceutical market operates once TrumpRx becomes active.